Eugene Eddlemon, MD
Vascular Surgery · Cleveland, TNNPI 1871525477
Payments from drug & device makers
Across 27 payments — averaging $59.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- W. L. Gore & Associates, Inc.$367
- Shockwave Medical, Inc$340
- Silk Road Medical, Inc.$296
- Abbott$257
- Cook Medical LLC$143
- Bard Peripheral Vascular, Inc.$94
- plus $114 from 4 others
What the payments were for
- Food & beverage$1,611100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| W. L. Gore & Associates, Inc. | 3 | $367 |
| Shockwave Medical, Inc | 8 | $340 |
| Silk Road Medical, Inc. | 3 | $296 |
| Abbott | 2 | $257 |
| Cook Medical LLC | 1 | $143 |
| Bard Peripheral Vascular, Inc. | 6 | $94 |
| Penumbra, Inc. | 1 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $23 |
| Medtronic | 1 | $19 |
| Angiodynamics, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$283
- ENROUTE Transcarotid Neuroprotection System$266
- EXCLUDER Iliac Branch Endoprosthesis$147
- Zenith$143
- ENROUTE Transcarotid Stent$136
- ESPRIT$136
- ENROUTE Transcarotid Stent System$130
- ENHANCE Transcarotid Peripheral Access Kit$130
- ENROUTE 0.014 Guidewire$130
- Perclose ProGlide suture mediated closure system$121
- EXCLUDER Conformable AAA Endoprosthesis with Active Control$113
- EXCLUDER AAA Endoprosthesis$107
How this compares
$1,611 in reported general payments places this provider in the 20th percentile of 117 vascular surgery providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 21 | $11,936 |
| Cilostazol | 248 | $3,905 |
| Pentoxifylline | 18 | $397 |
| Ropinirole Hcl | 21 | $388 |
| ClopidogrelClopidogrel Bisulfate | 55 | $256 |
| Gabapentin | 16 | $140 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 19 | $127 |
| Atorvastatin Calcium | 21 | $117 |
| Amlodipine Besylate | 11 | $4 |
Paid to pharmacies, not to this prescriber.
Other vascular surgery in Cleveland
- Daniel ClairNashville$1.5M
- Anton Dias PereraGermantown$832K
- Thomas NaslundNashville$566K
- Bryan FisherHendersonville$444K
- Christopher LesarChattanooga$320K
- Mark IafratiNashville$203K
- Mark FugateChattanooga$178K
- Robert AllenKingsport$147K
- Billy KimMount Juliet$140K
- William HarrisChattanooga$124K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.